Navigation Links
Sangamo Announces Pricing of Public Offering of Common Stock
Date:4/8/2011

clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's public offering of common stock, the anticipated timing of the closing of the offering, the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the comp
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
2. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
6. Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
7. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
8. Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference
9. Sangamo BioSciences to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
11. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... , Aug. 18, 2014 BioElectronics ... advanced consumer medical devices said that its ... interviewed by CEOLIVE.TV as part of its ... interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... explains to investors the unique advantages of ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ("we" ... and marketing of innovative therapies for autoimmune diseases in ... a second notice of TNI BioTech,s annual meeting of ... Noreen Griffin , founder and CEO of TNI ... participation in the Annual Meeting. On behalf of our ...
(Date:8/18/2014)... , 18. August 2014 Vier ... eine internationale klinische Studie auf, in der ... Linse soll das Sehvermögen bei allen Entfernungen ... Operation möglicherweise keine Lese- oder Gleitsichtbrille mehr ... Namen FluidVision Accommodating Intraocular Lens ...
Breaking Biology Technology:BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 2Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 3Implantation einer revolutionären akkommodativen Linse bei Katarakt-Patienten in deutschen Augenzentren im Rahmen einer internationalen klinischen Studie 4
... 5 Compendia Bioscience today,announced that it ... (NYSE: GSK ) for Oncomine(TM) Enterprise ... Oncomine.,Oncomine Enterprise Edition builds upon the features ... the ability to securely,view proprietary gene expression ...
... American Oriental,Bioengineering (NYSE: AOB ) announced ... offering. The decision to cancel its,convertible preferred stock ... market conditions resulting in terms that were not ... Statements made in this press release are ...
... Exelixis,Inc. (Nasdaq: EXEL ) announced earlier today ... Deerfield Management. The arrangement will,be discussed by Exelixis management ... ET today, Thursday, June 5. To listen to a ... Investors at, http://www.exelixis.com ., A replay of the ...
Cached Biology Technology:GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience 2
(Date:8/19/2014)... treat pain, but its effect on pain following ... recent study reported on the Neural Regeneration ... models of an avulsion injury to the left ... pain) were given electroacupuncture stimulation at bilateral Quchi ... After electroacupuncture therapy, chronic neuropathic pain in the ...
(Date:8/19/2014)... forms, they have not been widely used due to ... the University of Surrey and Trinity College Dublin have ... graphene, to create a flexible sensor that is sensitive ... , Once treated, the rubber bands remain highly ... imparts an electromechanical response on movement the team ...
(Date:8/18/2014)... , August 19, 2014 ... biometric authentication in smart devices  Trustonic, ... for smart devices, and Fingerprint Cards AB (FPC) ... of FIDO Ready™ secure biometric authentication on connected ... touch fingerprint sensors (FPC1020, FPC1021 and FPC1150) and ...
Breaking Biology News(10 mins):Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 2Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 3Trustonic and Fingerprint Cards Collaborate to Bring Secure Biometrics to Connected Devices 4
... OAK RIDGE, Tenn., Oct. 4, 2010 -- Supercomputer ... are helping scientists unravel how nucleic acids could have contributed ... team led by Jeremy Smith, who directs ORNL,s Center for ... Tennessee, used molecular dynamics simulation to probe an organic chemical ...
... Rochelle, NY, October 4, 2010 Briefings in Palliative, Hospice, ... Journal of Palliative Medicine published by Mary ... announce a collaboration with The Institute for Palliative Medicine,s ... to create a new monthly feature for the e-newsletter. ...
... Can diet affect our children,s long-term mental and ... number of international leading experts on child nutrition next ... organized within the 7th Framework Programme Nutrimenthe, entitled "Effect ... The European Project Nutimenthe -funded by the European Commission ...
Cached Biology News:Powerful supercomputer peers into the origin of life 2PAL-MED CONNECT partners with Briefings in Palliative, Hospice, and Pain Medicine & Management 2Experts will meet to discuss how diet affects behavioral development of children 2
Detect and measure levels of mouse IgG2b antibody isotypes quickly and easily....
... state of the Art GLP facility ... dual 38,000 L fermentation. Coordinated ... production. Aseptic operation capable of ... and Continuous Modes. Hosts include: ...
Request Info...
Immunogen: VDAC3 Protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: